表决结果：赞成票3票，反对票0票，弃权票0票。 特此决议！ 悦康药业集团股份有限公司 悦康药业集团股份有限公司（以下简称"公司"）第二届董事会独立董事专 门会议2024年第二次会议于2024年10月30日召开，本次会议应参会独立董事3名， 实际参会独立董事3名，本次会议由独立董事程华女士召集并主持。本次会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《悦康药 业集团股份有限公司章程》的规定，会议决议合法、有效。 二、独立董事专门会议审议情况 （一）审议通过《关于新增2024年度日常关联交易预计的议案》 公司本次新增 2024 年度日常关联交易预计事项属于公司日常经营业务实际 需要，交易双方按照公平、公正、公开原则开展，交易双方平等协商参照市场 价格确定交易价格，不存在损害公司股东尤其是中小股东的利益，不会对公司 独立性产生影响，公司业务不会因此对关联方形成依赖或被其控制。因此，同 意本次新增日常关联交易预计事项，并同意将该议案提交公司董事会审议。 悦康药业集团股份有限公司 第二届董事会独立董事专门会议 2024 年第二次会议决议 一、独立董事专门会议召开情况 独立董事：陈可冀、王波、程华 ...

证券代码：688658 证券简称：悦康药业 公告编号：2024-050 悦康药业集团股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 20 日（星期三）上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2024 年 11 月 20 日上午 10:00-11:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：于伟仕 投资者可于 2024 年 11 月 13 日（星期三）至 11 月 19 日（星期二）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过悦康药业集团股份有限 公司（以下简称"公司"）邮箱 irm@youcareyk.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 ...

证券代码：688658 证券简称：悦康药业 公告编号：2024-045 原药品批准文号：国药准字 H20123348 悦康药业集团股份有限公司 自愿披露关于注射用头孢美唑钠 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，悦康药业集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的关于注射用头孢美唑钠（规格：0.5g）的《药品补充申请批准 通知书》（通知书编号：2024B04703），该药品通过仿制药质量和疗效一致性 评价。 一、上述药品的基本情况 药品名称：注射用头孢美唑钠 剂型：注射剂 规格：0.5g（按 C₁₅H₁₇N₇O₅S₃计） 注册分类：化学药品 上市许可持有人：悦康药业集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关于仿制药质量和疗 效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于 开展化学药品注射剂仿制药质量和疗效一致性评价工作 ...

Group 1: Company Overview - The company is named YK Pharmaceutical Group Co., Ltd. with stock code 688658 [1] - The investor relations activity involved multiple prominent funds and securities firms [2] Group 2: Product Development - The Ginkgo biloba extract injection is primarily used in departments such as internal medicine, cardiovascular, and endocrinology, with expected growth in usage in otolaryngology and geriatrics [2] - The hydroxyl safflower yellow A injection is currently in the NDA stage [2] - The company has established a platform for small nucleic acid drugs and mRNA vaccine development, enhancing its R&D capabilities across the entire chain from target selection to clinical trials [3] Group 3: Innovations and Patents - The company has achieved significant breakthroughs in nucleic acid drug delivery technology, obtaining 10 invention patents by the end of 2023 [3] - The first siRNA drug targeting PCSK9, YKYY015, has received a national invention patent and is undergoing international patent application [4] - Preclinical studies show that YKYY015 exhibits significant inhibition of the target gene PCSK9 with an IC50 value of less than 1 nM [4] Group 4: Marketing and Sales Strategy - The company has a mature marketing system and plans to optimize its sales channels and enhance collaboration with large pharmaceutical distribution companies [4] - Continuous academic promotion and professional training for sales personnel are part of the strategy to strengthen the marketing network [4] Group 5: Compliance and Communication - The company ensures compliance with legal regulations and maintains transparent communication with investors, adhering to its information disclosure management system [5]

悦康药业集团股份有限公司 第二届董事会独立董事专门会议 2024 年第一次会议决议 一、独立董事专门会议召开情况 悦康药业集团股份有限公司（以下简称"公司"）第二届董事会独立董事专 门会议2024年第一次会议于2024年9月30日召开，本次会议应参会独立董事3名， 实际参会独立董事3名，本次会议由独立董事程华女士召集并主持。本次会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《悦康药 业集团股份有限公司章程》的规定，会议决议合法、有效。 二、独立董事专门会议审议情况 （一）审议通过《关于新增2024年度日常关联交易预计的议案》 公司新增2024年度日常关联交易预计事项属于公司日常经营业务实际需要， 交易按照公平、公正、公开原则开展，交易双方平等协商参照市场价格确定交 易价格，不存在损害公司股东尤其是中小股东的利益；关联交易事项对公司独 立性没有影响，公司业务不会因此对关联方形成依赖或被其控制。因此，我们 同意本次新增日常关联交易预计事项，并同意将该议案提交公司董事会审议。 表决结果：赞成票3票，反对票0票，弃权票0票。 特此决议！ 悦康药业集团股份有限公司 独立董事：陈可冀、王波、程华 2 ...

证券代码：688658 证券简称：悦康药业 公告编号：2024-043 悦康药业集团股份有限公司 关于新增 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）新增日常关联交易履行的审议程序 悦康药业集团股份有限公司（以下简称"公司"）于 2024 年 9 月 30 日召开 第二届董事会第十五次会议、第二届监事会第十三次会议，审议通过了《关于 新增 2024 年度日常关联交易预计的议案》，本次新增日常关联交易预计金额合 计为 5,800 万元人民币（不含税）。关联董事于伟仕、于飞、于鹏飞回避表决， 出席会议的非关联董事一致同意该议案，审议程序符合相关法律法规的规定。 本次新增日常关联交易预计事项事前已经公司第二届董事会独立董事专门 会议 2024 年第一次会议审议通过，全体独立董事一致认为：公司新增 2024 年 度日常关联交易预计事项属于公司日常经营业务实际需要，交易按照公平、公 正、公开原则开展，交易双方平等协商参照市场价格确定交易价格， ...

证券代码：688658 证券简称：悦康药业 公告编号：2024-044 悦康药业集团股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2024 年 9 月 30 日，悦康药业集团股份有限公司（以下简称"公司"）召开 了第二届监事会第十三次会议（以下简称"本次会议"）。本次会议由监事会主 席滕秀梅女士主持，会议应出席监事 3 人，实际出席并表决的监事 3 人。本次 会议的召开及表决程序符合《中华人民共和国公司法》、《悦康药业集团股份有 限公司章程》等相关规定。 二、监事会会议审议情况 监事会认为：公司本次预计新增的日常关联交易事项为公司开展日常经营 活动所需，交易双方以平等互利为合作基础，参考市场公允价格进行协商定价， 交易价格公允，不存在损害公司及股东利益的情形，不影响公司的独立性，上 市公司亦不会因此类交易而对关联人产生依赖。 表决结果：赞成票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见本公司于上海证券交易所网站(www.sse.com.c ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3]. Core Views - The company is focusing on major products, with traditional products gradually recovering from the impact of centralized procurement, which is expected to lead to a return to growth [1]. - The cardiovascular sector is the core area for the company, with key products such as Ginkgo biloba extract injection and Huoxintang (concentrated pill) expected to drive performance [1][12]. - Multiple potential blockbuster products are nearing market launch, including Hydroxy Safflower Yellow A for stroke treatment and Compound Ginkgo Leaf Tablets for vascular dementia [1][23]. - The company is actively investing in innovative fields such as small nucleic acids and peptides, with several new drug candidates in development [1][20]. Summary by Sections 1. Company Overview - The company integrates new drug research and development, manufacturing, distribution, and international trade, with a comprehensive production capability across raw materials, excipients, and formulations [8]. - It has a diverse product portfolio covering various therapeutic areas, including cardiovascular, diabetes, digestive, oncology, antiviral, and reproductive health [8][12]. 2. Cardiovascular Product Focus - The company has a rich product layout in the cardiovascular field, with Ginkgo biloba extract injection being a core product contributing significantly to revenue [1][23]. - The market for cardiovascular traditional Chinese medicine is growing, with the retail market expected to continue expanding [24]. 3. Impact of Centralized Procurement - The negative impact of centralized procurement on traditional generic drugs is gradually clearing, allowing for a recovery in sales [1][16]. - The company anticipates that the short-term effects of centralized procurement will diminish, leading to improved sales performance [1]. 4. Financial Forecast and Investment Recommendations - Revenue projections for 2024, 2025, and 2026 are estimated at 43.5 billion, 47.8 billion, and 54.0 billion CNY, respectively, with growth rates of 4%, 10%, and 13% [1]. - Net profit forecasts for the same years are 3.0 billion, 4.1 billion, and 5.1 billion CNY, with growth rates of 63%, 35%, and 27% [1].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance in the near term [3]. Core Insights - The company reported a revenue of 1.95 billion yuan for the first half of 2024, a year-on-year decrease of 11.36%, with a net profit attributable to shareholders of 119 million yuan, down 42.75% year-on-year [3]. - The decline in revenue is primarily attributed to a decrease in sales of its core product, Ginkgo biloba extract injection [3]. - The company is expected to enter a growth phase with its innovative traditional Chinese medicine products, including Hydroxy Safflower Yellow A, which has completed Phase III clinical trials and is anticipated to be approved for market in the first half of 2025 [4]. - The company has increased its R&D investment, which reached 202 million yuan in the first half of 2024, a year-on-year increase of 12.21% [4]. - Profit forecasts for the company indicate a net profit of 327 million yuan in 2024, 428 million yuan in 2025, and 533 million yuan in 2026, representing growth rates of 77%, 31%, and 25% respectively [4]. Financial Summary - For the first half of 2024, the company reported a gross margin of 58.30%, down 8.1 percentage points year-on-year, mainly due to rising production costs of anti-infection products [3]. - The company's total revenue for 2024 is projected to be 4.15 billion yuan, with a slight decrease from 2023 [5]. - The earnings per share (EPS) for 2024 is estimated at 0.73 yuan, with a price-to-earnings (PE) ratio of 26 [5]. - The company’s total assets are expected to grow from 5.91 billion yuan in 2023 to 6.91 billion yuan in 2026 [6].

Investment Rating - The report maintains a "Buy" rating for the company [2][3] Core Views - The company reported a revenue of 1.95 billion yuan for the first half of 2024, a year-on-year decrease of 11.36%, and a net profit attributable to shareholders of 119 million yuan, down 42.75% year-on-year [3] - The company is increasing its R&D investment, with R&D expenses rising by 12.21% compared to the same period last year, leading to a slight decline in gross margin to 58.30%, down 8.1 percentage points year-on-year [3] - The company is advancing its product pipeline, with significant developments including the acceptance of the NDA application for Hydroxy Safflower Yellow A and the completion of Phase III clinical trials for several products [3] - Future profit forecasts estimate net profits of 301 million yuan, 381 million yuan, and 459 million yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 28.3, 22.3, and 18.5 [3] Financial Summary - The company achieved a total revenue of 4.196 billion yuan in 2023, projected to decrease to 4.077 billion yuan in 2024, before increasing to 4.601 billion yuan in 2025 and 5.067 billion yuan in 2026 [4][5] - The net profit for 2023 was 185 million yuan, expected to rise to 301 million yuan in 2024, 381 million yuan in 2025, and 459 million yuan in 2026 [4][5] - The gross margin is projected to be 62.7% in 2023, slightly decreasing to 62.3% in 2024, and then recovering to 63.3% in 2025 and 64.0% in 2026 [4][5] - The company's total assets were reported at 5.856 billion yuan, with a total market value of 8.514 billion yuan [4]